The development of chronic kidney disease (CKD) is accompanied by a progressive decrease in the ability to produce 1,25-dihydroxyvitamin D. Pharmacological replacement with active vitamin D therefore has been a cornerstone of secondary hyperparathyroidism therapy in the end-stage renal disease population treated by long-term dialysis. Recent evidence suggests that extrarenal conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D may have significant biological roles beyond those traditionally ascribed to vitamin D. Furthermore, low 25-hydroxyvitamin D levels are common in patients with all stages of CKD. This article focuses on the role of nutritional vitamin D replacement in CKD and aims to review vitamin D biology and summarize the existing literature regarding nutritional vitamin D replacement in these populations. Based on the current state of the evidence, we provide suggestions for clinical practice and address areas of uncertainty that need further research. Am J Kidney Dis. 60(1):139-156.
INTRODUCTION
The first scientific descriptions of rickets were made in the mid-17th century. However, it was not until the 20th century that a low level of vitamin D, a nutritional fat-soluble component, was identified as a causative factor for rickets through the independent experiments of Edward Mellanby and Elmer McCollum. 1 A few years prior to this discovery, scientists Alfred F. Hess and Lester J. Unger had shown that exposing children with rickets to sunlight could cure the disease. 2 The exact chemical linking this nutritional fat-soluble component and sunlight subsequently was identified as ergosterol in 1927 through pioneering work by Nobel Laureate Adolf Windaus. 3 Through a series of experiments in 1930s, Windaus identified the chemical structure of vitamin D produced in the skin--cholecalciferol. He also described the structure of its parent molecule, 7-dehydrocholesterol. In 1931, Askew et al 4 identified the chemical structure of vitamin D found in irradiated foods (ergocalciferol). In the years to come, 25(OH)D and 1,25-dihydroxyvitamin D (1, 25 [OH] 2 D) were isolated, vitamin D receptor (VDR) was identified, and the role of vitamin D in bone mineral metabolism was outlined. The enzyme responsible for conversion of 25(OH)D to 1,25(OH) 2 D was identified in the kidneys and it was shown that as kidney function deteriorates, production of 1,25(OH) 2 D decreases. [5] [6] [7] With the availability of active vitamin D analogues in the 1980s and 1990s, 8, 9 data supporting their role in the management of secondary hyperparathyroidism, 10 and survival benefits seen in prospective observational studies, [11] [12] [13] they have become widely used therapy in long-term dialysis patients. Circulating 1,25(OH) 2 D generated from the kidney appears to drive most endocrine functions of vitamin D, such as its effects on calcium transport and mineral metabolism. Additional tissues, including prostate, breast, colon, testes, myocardium, pancreas, and components of the immune system, also express 1␣-hydroxylase, and VDR is expressed ubiquitously. [14] [15] [16] [17] [18] [19] [20] [21] Local production of 1,25(OH) 2 D from 25(OH)D likely is necessary for additional autocrine or paracrine functions. 22 In these scenarios, adequate circulating levels of 25(OH)D (derived from sun exposure or nutritional sources), rather than 1,25(OH) 2 D, may be essential. Furthermore, benefits from active vitamin D analogues seen in prospective cohort studies of patients with CKD and long-term dialysis patients have not been shown consistently in randomized controlled trials, 23, 24 and low 25(OH)D levels are highly prevalent in these populations. 13, [25] [26] [27] Given the relatively low cost of nutritional vitamin D and the potential benefit in conjunction with active analogues, it is important to evaluate the role of these supplements. Clinical practice guidelines provided by the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) recommend measuring 25(OH)D in patients with stages 3 and 4 CKD with accompanied secondary hyperparathyroidism, and if levels are Ͻ30 ng/mL, administering nutritional vitamin D prior to considering an active vitamin D analogue. 28 The KDIGO (Kidney Disease: Improving Global Outcomes) guideline includes similar suggestions. 29 However, for patients requiring dialysis, no specific recommendation is made regarding the role of nutritional vitamin D replacement. In addition, these guidelines have been criticized as being opinion based 24 and derived largely from observational data, 30 and there is a tremendous amount of confusion regarding nutritional vitamin D replacement in patients with CKD and those with ESRD treated by long-term dialysis.
In this review, we summarize vitamin D biology, discuss the existing literature regarding nutritional vitamin D replacement in these populations, provide clinical recommendations, and address areas of uncertainty that need further research.
VITAMIN D TERMINOLOGY
The terminology related to vitamin D has been confusing and inconsistent. 31 This is due in part to the fact that various forms of vitamin D exist (Table 1 ; Fig  1) . 32 For this review, we have applied the following terminology: ergocalciferol and cholecalciferol are referred to as nutritional vitamin D. Calcitriol, 1-␣ calcidiol, paricalcitol, doxercalciferol, and maxacalcitol are referred to as active vitamin D. All the vitamin D compounds have structures similar to steroids, with the exception that the bond between carbon atoms 9 and 10 is broken. A wide range of criteria are used to define vitamin D deficiency, and unfortunately, there is no consensus on this issue. [33] [34] [35] [36] Many clinicians define serum 25(OH)D levels Ͻ20 ng/mL as deficient, 20-29.9 ng/mL as insufficient, and Ն30 ng/mL as sufficient (Table 2 ). There also is controversy regarding the upper limit of normal, with different cutoffs of 50-150 ng/mL proposed by different experts.
33, 35 A recent Institute of Medicine report considers 20 ng/mL as a "sufficient" level of vitamin D status for bone health. 37 However, it is important to consider that the optimal vitamin D level may vary per the disease outcome considered. Levels Ͼ10 ng/mL are optimal for the prevention of rickets and osteomalacia, whereas to maximally prevent secondary hyperparathyroidism or osteoporosis, levels Ͼ30 ng/mL may be needed.
38,39

VITAMIN D METABOLISM
Key steps in the metabolism are shown in Fig 2. 
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In healthy individuals, 7-dehydrocholesterol in the skin is exposed to UV rays (wavelength, 285-310 nm) in sunlight, leading to its conversion to previtamin D. 41 Previtamin D then isomerizes in a temperaturedependent manner to form cholecalciferol. Stamp et al 42 reported that brief casual exposure of ϳ20% of body surface area to sunlight is equivalent to ingesting 200 IU (5 g) of cholecalciferol. Repeated total-body exposure sufficient to cause mild erythema can increase plasma 25(OH)D level as much as long-term ingestion of 10,000 IU (250 g) of cholecalciferol per day. 41, 42 Cutaneous production of cholecalciferol thus is highly efficient. However, many individuals lack the necessary exposure to UV light to maintain adequate stores. In individuals who are elderly, have higher melanin levels, have low baseline UV exposure, or are uremic, cutaneous production of cholecalciferol is reduced. 19, 43, 44 In these cases, cutaneous production can be supplemented with dietary sources of vitamin D, including both plant (ergocalciferol) and animal (cholecalciferol) forms. These dietary forms are incorporated into chylomicrons and are transported through the lymphatic system into venous circulation. Both the dietary form and vitamin D produced in the skin can be stored in and released from fat cells. Most of the stored form of vitamin D in adipose tissue is cholecalciferol. 45 Vitamin D is transported to the liver, where it undergoes hydroxylation of the 25th position by cytochrome P450 enzymes to become 25(OH)D, also known as calcidiol.
19 CYP2R1 has been described as the key enzyme for this process; however, CYP2D11 and CYP2D25 are also believed to be involved. 46, 47 54 In the mitochondria, 25(OH)D is converted to 1,25(OH) 2 D by the cytochrome P450 enzyme 1␣-hydroxylase (CYP27B1) and returned to the circulation as the active form of vitamin D. 55 Although initial studies identified 1␣-hydroxylase in proximal tubular cells, this enzyme is also found in other parts of the nephron, including the distal tubules and collecting duct. 56 In states of vitamin D deficiency, the distal nephron is a major site of 1␣-hydroxylase expression. 57 Another mitochondrial enzyme, 24␣-hydroxy- 19, 33, 59 It has been reported that this receptor directly or indirectly controls the function of more than 200 genes. 19, 59 In the gastrointestinal tract, active vitamin D promotes enterocyte differentiation and is capable of increasing calcium and phosphorus absorption. 33, 60 In bone, active vitamin D can stimulate osteoclast activity through an increase in RANKL (receptor activator of nuclear factor-B ligand) expression, leading to release of calcium into the circulation.
33, 61 Vitamin D, along with PTH, can further stimulate calcium absorption from the distal tubule in the kidney. 59 Active vitamin D in turn suppresses the release of PTH. In addition to effects on bone metabolism, active vitamin D may regulate other cellular functions. Central roles of active vitamin D have been described in the maintenance of muscle function, 62,63 blood pressure and cardiovascular health, [63] [64] [65] [66] glucose control, 67 both innate and acquired immune systems, [68] [69] [70] [71] [72] and brain function 73, 74 and in the prevention of certain cancers. 21, 75, 76 Through VDR, active vitamin D regulates processes such as cellular proliferation, differentiation, apoptosis, and angiogenesis in different tissues. 21 Renal cytochrome P450 enzyme 1␣-hydroxylase (CYP27B1) is tightly regulated by PTH, serum calcium and phosphorus, and fibroblast growth factor 23 (FGF-23). 47 Low serum calcium, low serum phosphorus, and high PTH levels stimulate this enzyme to increase the synthesis of active vitamin D, which in turn suppresses PTH production. FGF-23 has been shown to inhibit production of active vitamin D by inhibiting 1␣-hydroxylase (CYP27B1) expression and simultaneously increasing 24␣-hydroxylase (CYP24A1) expression, leading to production of inactive metabolites of vitamin D. 77 Active vitamin D also increases 24␣-hydroxylase (CYP24A1) expression to convert 1,25(OH) 2 D and 25(OH)D to inactive forms. 78 However, PTH decreases 24␣-hydroxylase (CYP24A1) enzyme activity.
VITAMIN D METABOLISM IN CKD
Calcidiol Deficiency
Serum 25(OH)D levels begin to decrease in stage 2 CKD, 79, 80 and vitamin D deficiency is prevalent in all subsequent stages of CKD, 25,81-84 including ESRD treated by long-term dialysis. 26, 85 Multiple factors have been reported to be responsible for this (Box 1). Patients with CKD are likely to have reduced sun exposure, 86, 87 and uremic patients have impaired skin synthesis of endogenous vitamin D in response to UV light. 43, 88 Hyperpigmentation, frequently seen in patients with advanced kidney disease, may impair the dermal synthesis of endogenous vitamin D.
25,89 Furthermore, intake of foods rich in vitamin D (eg, dairy products) is decreased in patients with CKD, and uremia may impair gastrointestinal vitamin D absorption. [90] [91] [92] [93] [94] Proteinuria may be accompanied by high urinary loss of vitamin D-binding protein, leading to increased renal loss of all vitamin D metabolites. 81, 90, 95, 96 Patients on peritoneal dialysis therapy may lose 25(OH)D and vitamin D-binding protein in peritoneal dialysis fluid. [97] [98] [99] Although not well supported, a possibility also has been raised that CKD may impair hepatic conversion of cholecalciferol to calcidiol.
25
Calcitriol Deficiency
In individuals without kidney disease, renal 1␣-hydroxylase is regulated by 1,25(OH) 2 D and is less dependent on the available substrate. 35 As CKD advances, renal 1␣-hydroxylase becomes progressively more substrate dependent, and less availability of substrate for reasons outlined earlier will lead to lower 1,25(OH) 2 D production. 27, 35, 81, 94, 100, 101 This reduced availability of substrate 25(OH)D is accompanied further by additional factors as outlined next that lead to low levels of 1,25(OH) 2 D in patients with CKD and those with ESRD treated by long-term dialysis (Box 1).
Reduction in renal mass is associated with reduced availability of 1␣-hydroxylase. 7, 102 However, this is unlikely to be the sole mechanism responsible for 1,25(OH) 2 D deficiency because 1,25(OH) 2 D levels are shown to be low even in patients with only mildly decreased kidney function. Renal 1␣-hydroxylase is downregulated by elevated serum phosphorus 103 and elevated FGF-23 levels. [104] [105] [106] Renal 1␣-hydroxylase activity also is thought to be suppressed by acidic, hyperuricemic, and uremic milieus. [107] [108] [109] [110] [111] A decrease in glomerular filtration rate will lead to reduced filtration of the 25(OH)D-vitamin D-binding protein complex that will further limit delivery and uptake of this complex by the receptors megalin and cubulin in renal tubular cells. 54, 112, 113 CKD also is associated with decreased expression of megalin. 114 Furthermore, secondary hyperparathyroidism associated with low vitamin D levels depletes vitamin D body stores by promoting 24,25-dihydroxy hydroxylases. Elevated FGF-23 levels also induce 24-hydroxylase, which degrades 1,25(OH) 2 D. 105 The effects of CKD on extrarenal 1␣-hydroxylase are unclear. 24, 115 Experimental and clinical data have shown that administration of nutritional vitamin D even in anephric individuals is associated with significant increases in 1,25(OH) 2 D levels. This suggests that extrarenal production of active vitamin D can be induced by nutritional vitamin D supplements in patients with advanced CKD. 16, 115 Effects of FGF-23 on nonrenal 1␣-hydroxylase are unclear; however, speculation that nonrenal 1␣-hydroxylase is regulated differently than the renal 1␣-hydroxylase and the wellestablished fact that vitamin D has several autocrine/ paracrine functions opens the door for the possibility that nutritional vitamin D, even in patients with CKD and long-term dialysis patients, may help correct adverse consequences of vitamin D insufficiency and deficiency.
Vitamin D Resistance
In advanced CKD, there is progressive loss of VDR in the parathyroid gland, leading to vitamin D resistance. 116 In addition, low levels of active vitamin D further lead to impairment in the binding of active vitamin D to VDR, as well as in the binding of the vitamin D-VDR complex to the vitamin D response element. 117, 118 Thus, CKD is characterized by both low vitamin D levels and vitamin D resistance.
VITAMIN D STATUS AND OUTCOMES
Evidence in Populations Without CKD
Multiple ecologic, cross-sectional, and longitudinal observational studies have reported a significant inverse association between serum 25(OH)D levels and cardiovascular outcomes in populations without established CKD. [119] [120] [121] [122] [123] These studies have been conducted in different populations, including elderly patients, 124 male health care professionals, 125 patients referred for cardiac angiography, 126, 127 and general populations. 128, 129 Results from these studies have reported up to 2-3 higher magnitudes of cardiovascular outcomes in patients with vitamin D deficiency when comparisons are made between the highest and lowest levels of serum 25(OH)D. However, as noted in a recent meta-analysis by Pittas et al, 64 these observations have not been uniformly confirmed in longitudinal observational studies and randomized controlled trials. Pittas et al 64 summarized data regard- ing the association between vitamin D status and cardiometabolic outcomes from 13 longitudinal observational studies and 18 trials. Studies involving patients with CKD were excluded. Outcomes included incident hypertension, incident type 2 diabetes, and incident cardiovascular events, such as myocardial infarction, stroke, and cardiovascular-related death, in generally healthy adults. The review authors concluded that the association between vitamin D status and cardiometabolic outcomes is uncertain. They observed a higher risk of incident hypertension in cohorts with low serum 25(OH)D levels (relative risk, There is a paucity of clinical data regarding whether nutritional vitamin D supplementation improves noncardiometabolic outcomes such as infections. A study by Fabri et al 72 has recently shown in in vitro experiments a vitamin D-dependent pathway that is involved in acquired T-cell immune response mediated by interferon ␥ against Mycobacterium tuberculosis. In vitamin D-sufficient sera, interferon ␥ induced this antimicrobial pathway in human macrophages. In vitamin D-deficient sera, this induction was not achieved, but supplementation with cholecalciferol restored the pathway, outlining a key role of nutritional vitamin D in immunity against infections such as tuberculosis. However, further clinical trials will be needed to confirm whether supplementation with nutritional vitamin D is associated with a decrease in infectious complications. A recent review from the Institute of Medicine on this topic, although controversial, has highlighted this lack of definitive data for the health benefits of vitamin D supplementation beyond bone health in the general population.
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Evidence in CKD Populations
Despite key alterations in vitamin D metabolism in patients with decreased kidney function, a similar story can be told when it comes to clinical data regarding associations between vitamin D status and outcomes. The prevalence of vitamin D deficiency in the general population has been described to range from 20%-50%, with race, age, sunlight exposure, and comorbid conditions such as diabetes mellitus and obesity accounting for wide variation in prevalence rates.
131- 133 Vitamin D deficiency is reported to have an even higher prevalence in the CKD population, with estimates as high as 70%-80% in some studies.
Wolf et al 13 [134] [135] [136] and vitamin D deficiency has been described to begin even before abnormalities in serum calcium, phosphorus, or PTH levels become detectable. 83 In cross-sectional studies, vitamin D deficiency has been described to be associated independently with albuminuria in adults participating in the Third National Health and Nutrition Examination Survey 137, 138 and also in other studies. 139 Vitamin D deficiency also has been identified as a contributor to racial disparity in albuminuria. 140 A number of studies have reported on the association between 25(OH)D levels and mortality in CKD populations. 82 A meta-analysis by Pilz et al 82 showed improving survival with increasing 25(OH)D levels in CKD populations requiring and not requiring dialysis treatments. In this analysis, an increase of 10 ng/mL in serum 25(OH)D level was associated with a 14% reduction in mortality risk (relative risk, 0.86; 95% CI, 0.82-0.91). Although the review is limited by potential publication bias and other limitations that are inherent to the included observational studies, it provides strong support for measuring 25(OH)D to identify high-risk subgroups within the CKD population.
Studies of the association between 25(OH)D levels and other important outcomes, such as cardiovascular events, coronary artery calcification, CKD progression, early GFR loss, and bone fractures in CKD, are summarized in Table 3 . 13, 137, [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] Recently, Drechsler et al 147 reported an analysis of data from the NECOSAD (Nederland Cooperative Study on the Adequacy of Dialysis) cohort and further explored the association between 25(OH)D levels and short-(6 months) and long-term (36 months) mortality in incident maintenance dialysis patients who were alive at 1 year after dialysis therapy initiation. The cohort used in this analysis was composed of 762 adult hemodialysis and peritoneal dialysis patients recruited over 13 years from 37 dialysis centers in the Netherlands. Even for those who had survived their first year on dialysis therapy, subsequent mortality rates were high (ϳ7% at 6 months and 30% at 36 months), and cardiovascular causes were responsible for Ͼ50% of these deaths. In analyses adjusted for possible confounders, including bone mineral metabolism parameters and seasonal variation in vitamin D levels, the authors reported higher cardiovascular mortality in patients with 25(OH)D levels Յ10 ng/mL compared with patients with 25(OH)D levels Ͼ10 ng/mL; adjusted hazard ratios were 2.72 (1.05-7.05; P ϭ 0.04) and 1.61 (1.00-2.57; P ϭ 0.048) for the 6-month and 3-year follow-up, respectively. In stratified analyses, patients with high PTH levels and 25(OH)D levels Յ10 ng/mL experienced more than a 3-fold higher risk of cardiovascular death compared with patients with high PTH levels and 25(OH)D levels Ͼ10 ng/ mL. No association was seen between vitamin D deficiency and noncardiovascular mortality, but few patients died of noncardiovascular causes. These results not only confirmed the previously reported associations between 25(OH)D levels and short-term clinical outcomes in dialysis patients, but also suggest that 25(OH)D level measured at 1 year after dialysis therapy initiation predicts long-term (3-year) cardiovascular mortality. These associations (both short and long term) were particularly prominent in a subgroup of patients with high PTH levels, raising the possibility that the patient population with severe underlying bone and mineral disorders is particularly more susceptible to adverse effects of low 25(OH)D levels. Studies such as that by Drechsler et al 147 are important 
NUTRITIONAL VITAMIN D REPLACEMENT IN CKD
The data presented here provide a convincing case for the association between serum 25(OH)D levels and clinical outcomes. Although definitive conclusions regarding causality cannot be made from such observational data, a natural question is whether supplementing nutritional vitamin D will provide clinical benefits and whether there may be adverse effects of such supplementation.
The CKD and long-term dialysis populations, with higher rates of vitamin D deficiency, cardiovascular events, and infections compared with the general population, represent ideal groups to evaluate the efficacy and safety of nutritional vitamin D supplementations. Reports of the use of vitamin D compounds in the setting of kidney disease appeared as early as the 1950s. In 1957, Stanbury 153 reviewed the thenavailable literature on this topic and reported that "Vitamin D steroids should not be given to patients in whom the predominant osseous lesion is renal osteitis fibrosa; even with full metabolic control, this would be little more than a hazardous therapeutic experiment." 153(p60) Subsequent case reports noted that the dose of cholecalciferol required to correct biochemical and bone abnormalities of renal osteodystrophy was in the magnitude of 100,000-300,000 IU/d, doses that carried a significant risk of hypercalcemia. 154 This led to testing whether calcitriol can achieve the same biochemical and bone histology corrections with a better adverse-effect profile.
Berl et al 155 conducted a double-blind controlled trial in patients on long-term dialysis therapy (n ϭ 31) comparing oral calcitriol (0.5-1.5 g/d) with cholecalciferol (400-1,200 IU/d) for 12 weeks. They concluded that effects of PTH lowering and improvements in bone histology that were seen with calcitriol were not observed in the cholecalciferol group. 155 Although 5 of 15 patients in the calcitriol group developed hypercalcemia, the authors noted that hypercalcemia was of shorter duration and also was easily reversible upon reducing the dose of calcitriol. Malluche et al 156 evaluated the effects of cholecalciferol on bone histology in patients with CKD with creatinine clearance of 30-80 mL/min/1.73 m 2 (n ϭ 36). They noted that intestinal absorption of calcium increased and was normalized in all patients. However, in 17 patients who underwent bone histology studies, cholecalciferol in doses that normalized intestinal absorption of calcium did not restore bone histology to normal after 18 months of therapy (17 patients). These early trials reporting the inferiority of nutritional vitamin D compound in patients with kidney disease and the subsequent availability of vitamin D compounds with fewer calcemic effects contributed to a lack of enthusiasm to study nutritional vitamin D supplements in patients with CKD and long-term dialysis patients for more than 2 decades. However, modern understanding of the biology of vitamin D as described earlier in this review has led to re-emergence of interest in this topic and a number of recent observational studies and randomized controlled trials have been conducted to evaluate this further (Tables 4  and 5) . [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] As reviewed in these tables and also previously reported, 24, 30 to date there are no welldesigned randomized controlled trials or large observational cohort studies that evaluate whether administration of nutritional vitamin D in patients with CKD improves patient-centered clinical outcomes, such as overall mortality, cardiovascular disease, or infection.
A recent systematic review and meta-analysis by Kandula et al 30 on this topic identified 17 observational cohort studies and 5 randomized controlled trials, noting that most studies conducted on this topic are of low to moderate quality. They noted a statistically significant increase in serum 25(OH)D levels (mean difference, 24.1 [95% CI, 19.6-28.6] ng/mL), along with a decrease in PTH levels (mean difference, Ϫ41.7 [95% CI, Ϫ55.8 to Ϫ27.7] pg/mL) in observational studies. In randomized controlled trials, there was a significant increase in serum 25(OH)D levels (mean difference, 14 [95% CI, 5.6-22.4] ng/mL) and an associated decrease in PTH levels (mean difference, Ϫ31.5 [95% CI, Ϫ57 to Ϫ6.1] pg/mL). A low incidence of hypercalcemia (up to 3%) and hyperphosphatemia (up to 7%) was reported with nutritional vitamin D supplementation. Both hypercalcemia and hyperphosphatemia resolved when vitamin D therapy and/or phosphate binders were withheld. However, none of the studies reported outcomes related to cardiovascular disease, bone disease, or mortality. This emphasizes the need for well-designed randomized controlled trials on this topic.
The clinical trial registry ClinicalTrials.gov lists several studies in both non-dialysis-dependent patients with CKD and long-term dialysis populations designed to assess biochemical and clinical outcomes. Although none of these studies is powered to detect differences in mortality or cardiovascular events, these studies will further enrich our understanding of vitamin D pathobiology by addressing the role of nutritional vitamin D on outcomes such as immune function (hCAP18 Levels and Vitamin D Deficiency in is Ͻ30 ng/mL. The recommended dose depends on the 25(OH)D level; 50,000 units of ergocalciferol once a week for 4 weeks followed by the same dose once a month for 4 months if level is Ͻ15 ng/mL, and 50,000 units once a month for 6 months if level is 20-30 ng/mL. Serum calcium and phosphorus should be monitored every 3 months. The need for continuing therapy with ergocalciferol is to be re-evaluated annually. These guidelines have been based on extrapolation of data from the general population and also have been largely opinion based rather than evidence based. However, because (1) there is reasonable evidence to support the safety of nutritional vitamin D supplements at the recommended doses and with suggested monitoring schedule in these guidelines, (2) there is evidence that nutritional vitamin D administration in patients with CKD is associated with decreases in PTH levels, and (3) there is biological evidence to support that these supplements may have extrarenal actions, it is reasonable to adopt the present guidelines in clinical practice. In humans, cholecalciferol is more effective than ergocalciferol in increasing 25(OH)D levels and dose determinations should take into account these potency differences, as well as the availability of the nutritional forms. 174 Future trials to address effects of nutritional vitamin D on patientcentered outcomes and trials comparing nutritional vitamin D with active vitamin D preparations are cused mainly on biochemical parameters of bone health and have not adequately addressed clinical outcomes associated with these biological pathways, and none of the studies to date has been adequately powered to address effects on hard outcomes such as mortality or cardiovascular events. Ongoing and future studies hopefully will address these issues.
CASE REVIEW
Case 1
This patient has secondary hyperparathyroidism in the setting of advanced CKD, vitamin D insufficiency, and normal serum calcium and serum phosphorus levels. As discussed in this review and also supported by the KDIGO and KDOQI guidelines, it will be reasonable to initiate therapy with ergocalciferol at 50,000 U/wk for 8 weeks. If serum 25(OH)D level remains Ͻ30 ng/mL (Ͻ74.88 nmol/L), repeat another 8-week course of 50,000 IU/wk of ergocalciferol. When the level is Ն30 ng/mL (Ն74.88 nmol/L), oral ergocalciferol is to be continued on a maintenance dose of 50,000 IU/mo. Oral cholecalciferol at 1,000-2,000 IU/d can be used as an alternative maintenance dose. Serum calcium and phosphorus should be monitored every 3 months. It will be important to keep in mind that although this strategy may improve biochemical parameters related to skeletal health, effects on extraskeletal health are unclear at this time.
Case 2
This patient has secondary hyperparathyroidism in the setting of ESRD, vitamin D insufficiency, and normal serum calcium and serum phosphorus levels. As in the prior case, it will be reasonable to initiate therapy with ergocalciferol at 50,000 U/wk for 8 weeks and follow the suggestions mentioned earlier, including close monitoring for hypercalcemia and hyperphosphatemia. However, it is important to consider that at present there is no clinical consensus to support whether the addition of nutritional vitamin D therapy in this scenario will have beneficial clinical effects, and further research is needed in this area. 
